First report of DG Competition pharma inquiry

DG Competition consultation (426 pages, PDF) on issues arising from the European Commission's inquiry into competition issues in pharmaceuticals.

The Commission's loudly trumpeted claim that delays to generic entry caused additional costs of EUR 3 billion appears to be on the following basis:

The document also tries to revive the Community Patent and European Patent Litigation Agreement ideas, claiming that “generic companies and originator companies are in agreement over the need for a single Community patent and the creation of a unified and specialised patent judiciary in Europe”.

There are no specific consultation questions — comments are invited generally. Responses by Saturday 31 January 2009.

For further information or advice please contact Franck Latrémolière.

Filed under DG Competition, Healthcare, Pharmaceuticals.

Reckon LLP is an economics consultancy with expertise in data analysis, economic regulation and competition law.

About Reckon